Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Johnson & Johnson : Janssen Pharmaceutical Companies - European Commission Approves Janssen's TREMFYA a First-in-Class Treatment for Active Psoriatic Arthritis

11/26/2020 | 09:09am EST

Belgium - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved TREMFYA (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.

Guselkumab is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor. It is already approved for the treatment of patients with moderate to severe plaque psoriasis. IL-23 is an important driver of the progression of inflammatory diseases including psoriasis and PsA, among others.1

PsA is a multifaceted, chronic, immune-mediated inflammatory disease that is progressive and is characterised by debilitating joint damage and inflammation, in addition to enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis. The pain, stiffness and swelling of the joints and connective tissue can be severe and cause everyday tasks to become difficult.2,3 In addition, more than half of people with PsA also live with another condition, such as cardiovascular disease, osteoporosis, inflammatory bowel disease or depression.4,5 There is currently no known cure for PsA, and it is estimated that up to a third of the 14 million people living with psoriasis in Europe will go on to develop PsA.6,7

'Psoriatic arthritis is a progressive and debilitating disease and can have a huge impact not only on quality of life, but also on a person's mental health. We welcome the news that guselkumab is now approved for the treatment of psoriatic arthritis,' said Jan Koren, President, European Federation of Psoriasis Patient Organisations (EUROPSO). 'For patients, having more innovative treatment options available that improve the quality of life is good news, which we believe will bring hope to many patients in need of additional treatment options. We must now work to make this treatment accessible to patients across the European Union.'

Approval for this new indication is based on results from the DISCOVER-1 and DISCOVER-2 Phase 3 clinical studies, which assessed safety and efficacy of guselkumab 100 mg q4w and q8w in adult patients with active PsA. DISCOVER-1 evaluated 381 participants with active PsA who had an inadequate response to standard therapies, including participants (30 percent) previously treated with anti-tumour necrosis factor (TNF) alpha biologics.8 DISCOVER-2 included 739 patients who were biologic-naive only and had an inadequate response to standard therapies.9 Data from these studies was published earlier this year in The Lancet (24-weeks; DISCOVER-1, DISCOVER 2).8,9

The published results show that in both studies, at week 24, adult patients with active PsA achieved statistical significance in the primary endpoint of American College of Rheumatology (ACR) 20 percent improvement (ACR20) response (DISCOVER-1: p

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about JOHNSON & JOHNSON
07:06a"MY 2021 HEALTHCARE RESOLUTION" : 7 Johnson & Johnson Leaders Share Their Goals ..
01/14JOHNSON & JOHNSON : Statement on Political Contributions
01/14NEXTECH AR : sees $7.3M in business for Q4
01/14US Stocks Rise in Early Trading Amid Expectations of Surge in Consumer Spendi..
01/14Presidency On Africa Centres for Disease Control and Prevention Securing Firs..
01/14The earnings season picks up steam
01/14THE COVID-19 DATA PLAN : 3 Innovative Ways Johnson & Johnson Is Using Data Scien..
01/14Invitae to Develop Standardized Panel to Detect Molecular Residual Disease as..
01/14270 Million Covid-19 Vaccine Doses Secured for Africa
01/13JOHNSON & JOHNSON : Favorable Data Published About Johnson & Johnson Covid-19 Va..
More news
Financials (USD)
Sales 2020 81 734 M - -
Net income 2020 15 924 M - -
Net Debt 2020 5 979 M - -
P/E ratio 2020 26,3x
Yield 2020 2,47%
Capitalization 423 B 423 B -
EV / Sales 2020 5,25x
EV / Sales 2021 4,76x
Nbr of Employees 132 200
Free-Float 84,3%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 165,78 $
Last Close Price 160,65 $
Spread / Highest target 12,7%
Spread / Average Target 3,19%
Spread / Lowest Target -13,5%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.08%422 918
ROCHE HOLDING AG0.99%301 476
NOVARTIS AG-0.16%214 006
MERCK & CO., INC.0.45%207 893
PFIZER INC.-0.16%204 271
ABBVIE INC.4.18%197 080